Zack Armen: This is incredibly exciting for patients with neoadjuvant colon and rectal cancer
Zack Armen, Head of Investor Relations at Agenus, shared a post by Pashtoon Kasi, Oncologist and researcher at Weill Cornell Medicine, on LinkedIn, adding:
”This is incredibly exciting for patients with neoadjuvant (pre-surgical) colon and rectal cancer, which unfortunately is growing in prevalence particularly among Americans under 50. Thank you Pashtoon Kasi and to the Weill-Cornell team for the work you’re doing to advance the treatment paradigm in solid tumor oncology.”
Quoting Pashtoon Kasi’s post:
”We have some incredible news.
NEST-2 BOT/BAL we are at our 12+ patients with MSS colorectal cancer within weeks! Further expansion approved.
Cohorts:
- MSS Colon n=77
- Plus a new MSS Rectal cohort n=30
- MSI-H n=15
Running with this story!”
Proceed to the article.
Source: Zack Armen/LinkedIn and Pashtoon Kasi/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023